MCMedicalCodingSoftware
813

MS-DRG 813: COAGULATION DISORDERS

DRGMedicalMDC 16

MS-DRG 813 is coagulation disorders, in MDC 16 (a medical DRG). Its FY2027 relative weight is 1.5257, so a case here pays more than the average Medicare inpatient stay (weight 1.0), with a geometric mean length of stay of 3.60 days. 40 ICD-10-CM principal diagnoses group into MS-DRG 813 under the CMS definitions manual; the most-searched are listed below.

FY2027 payment factors

Relative weight
1.5257
Geometric mean LOS
3.60
Arithmetic mean LOS
4.60
Post-acute transfer
No

Principal diagnoses that group to MS-DRG 813

From the CMS MS-DRG definitions manual’s principal-diagnosis index: 40 ICD-10-CM codes route here. The 24 most-searched:

  • D69.6Thrombocytopenia, unspecified
  • D66Hereditary factor VIII deficiency
  • D68.9Coagulation defect, unspecified
  • D69.3Immune thrombocytopenic purpura
  • R23.3Spontaneous ecchymoses
  • D69.2Other nonthrombocytopenic purpura
  • D65Disseminated intravascular coagulation [defibrination syndrome]
  • D68.2Hereditary deficiency of other clotting factors
  • D68.32Hemorrhagic disorder due to extrinsic circulating anticoagulants
  • D69.9Hemorrhagic condition, unspecified
  • D67Hereditary factor IX deficiency
  • D69.49Other primary thrombocytopenia
  • D69.59Other secondary thrombocytopenia
  • D68.4Acquired coagulation factor deficiency
  • D68.8Other specified coagulation defects
  • D69.0Allergic purpura
  • D69.8Other specified hemorrhagic conditions
  • D68.00Von Willebrand disease, unspecified
  • D68.01Von Willebrand disease, type 1
  • D68.020Von Willebrand disease, type 2A
  • D68.021Von Willebrand disease, type 2B
  • D68.022Von Willebrand disease, type 2M
  • D68.023Von Willebrand disease, type 2N
  • D68.029Von Willebrand disease, type 2, unspecified

16 more codes group here. Open any code above for its full hierarchy, or check a whole claim in the free DRG calculator.

Choosing the principal diagnosis: Hot flashes ICD-10 codes.

All FY2027 MS-DRGs · MDC 16

MS-DRG (IPPS Table 5)FY2027